-
High-level set the tone requires the normalization of drug collection institutionalization of collection and harvesting over the years
Time of Update: 2021-01-26
the meeting pointed out that in order to gradually solve the problem of expensive medical care, in recent years, the state has promoted the procurement and use of centralized drug volume major reforms, as of the end of last year has carried out three batches of collection, covering the average price of drugs reduced by 54%, saving more than 53 billion yuan a year, benefiting hundreds of millions of patients.
-
Significant adjustments to the sales team of well-known pharmaceutical companies
Time of Update: 2020-12-13
Novarma said in an email that the merger of the new Cardiovascular, Kidney and Metabolic Divisions is one of the strategic initiatives taken by the company to integrate resources, promote innovation, strengthen the grass roots and contribute to Novarma Pharmaceuticals' sustainable development in China, and the newly established division will also be directly connected to the CRM division, the headquarters of one of Novarce Pharmaceuticals' five global business units.
-
302 varieties are "advised to withdraw" no longer research and development, declaration
Time of Update: 2020-11-14
On September 7, the Chinese Pharmaceutical Society issued the Bulletin on the Release of the Sixth Batch of Over-Repeating Drug Tips, and published the List of Over-Repeating Varieties (Sixth Batch)
-
Industry concentration continues to increase, it is recommended to pay attention to generic pipeline rich leading pharmaceutical companies
Time of Update: 2020-08-29
In the industry believes that, with the normalization of production procurement into a final decision, the concentration of the generic pharmaceutical industry will continue to improve, the Chinese standard pharmaceutical companies are expected to further stabilize market share through collection, it is recommended to pay attention to the rich generic echelons, large-scale production capacity, RAW drug preparations integration of leading enterprises.
-
Pharmacies pay attention to a number of common drug modification instructions
Time of Update: 2020-08-01
Finishing: Cypress Blue - Pharmacy Manager Recently, according to the results of adverse drug reaction assessment, in order to further protect the public drug safety, the State Administration of Super
-
Astellas acquires a unique screening platform to help develop mitochondrial disease drugs
Time of Update: 2020-08-01
traditional drug screening platform, Dr. Kenji Yasukawa, President and CEO of Nanna's official website, said, "I believe this acquisition will enable Nanna's unique technology platform to combine our research and development capabilities for mitochondrial-related diseases to propose new solutions to address unmet medical needs." Nanna's platform will accelerate astellas' drug development in the field of mitochondria-related biology.
-
142 varieties called out of the health insurance point announced! Involved in a number of over a billion varieties
Time of Update: 2020-07-20
Pharmaceutical Network, June 24 June 23, Sichuan issued a notice on the transfer of some drugs out of the Sichuan Province Basic Medical Insurance, Industrial Injury Insurance and Maternity Insura
-
It's there! 142 kinds of drugs, out of the province's basic health insurance catalog
Time of Update: 2020-07-19
Guide: On June 23, , the Sichuan Health Insurance Bureau, the Department of Human Resources and Social Security jointly issued a circular announcing that six drugs, such as the conversion of sugar
-
Fosun Pharma receives approval of supplementary drug application slots issued by the State Drug Administration
Time of Update: 2020-06-09
recently, Shanghai Fosun Pharmaceutical (http:// (Group) limited shares company (http:// (hereinafter referred to as "Fosun Pharma"), its controlling subsidiary Shenyang Red Flag Pharmaceutic
-
New anti-lung cancer drug CM118 will enter clinical
Time of Update: 2020-06-03
Business Association March 6, Shanghai Re-New Pharmaceutical Technology Co., Ltd announced that the company's new anti-lung cancer drug CM118 project has completed preclinical research, and submitt
-
Misoprosol tablet consistency evaluation has been accepted China Resources, Xianyu rush to attack
Time of Update: 2020-06-02
Pharmaceutical Network August 15th, August 14th, Sendo Pharmaceuticals issued a notice that the company's misoprostol tablet consistency evaluation has been accepted, is currently under review and a
-
R & D of new coronavirus, a and B combined detection kits completed
Time of Update: 2020-02-25
Wen Feng mound Novel coronavirus pneumonia was reported in Guangzhou on February 23rd afternoon In a remote consultation with the Guangdong medical team in Jingzhou, Zhong Nanshan pointed out that the
-
R & D Daily: AstraZeneca imfinzi combination therapy is qualified to treat liver cancer orphans
Time of Update: 2020-01-21
Revolution plans to develop a new type of small molecule inhibitor; Hongyun Huaning new drug gma301 is approved for clinical application in China; RNA vaccine makes claudin car-t cells more effective
-
The number of medical representative posts will decrease rapidly
Time of Update: 2019-12-16
It's gone forever that this kind of industry opportunity can earn hundreds of thousands of dollars a year by eating rice and drinking tea every day Yesterday (December 14), Guangxi Medical Insurance B
-
In the first half of this year, antineoplastic drugs became popular new drugs, and the market will continue to rise in the future
Time of Update: 2019-07-23
[market analysis of pharmaceutical Station] in the first half of 2019, CDE undertook 3901 acceptance numbers Among the 145 new chemical drugs declared in the field of new drugs, there are more varieti
